Broad-scale analysis of thermodynamic signatures in medicinal chemistry: are enthalpy-favored binders the better development option?

Abstract:

:Thermodynamic profiles of ligand binding, particularly enthalpically favored binding signatures, have been suggested as a criterion to support the decision-making process around which compounds to select for further optimization in drug development. The concept was enthusiastically taken up, but turned out to be too superficial, either because many aspects determining thermodynamic profiles are insufficiently appreciated or because it is difficult to compare such data on a global scale. The impact of water, changes in protonation states, along with buffer dependencies and incompatible measurement conditions that are far from standard conditions hamper such broad-scale comparisons. However, thermodynamic signatures can make us aware of the impact of these aspects and provide important hints for improving our understanding of the binding process and defining criteria for drug optimization.

journal_name

Drug Discov Today

journal_title

Drug discovery today

authors

Klebe G

doi

10.1016/j.drudis.2019.01.014

subject

Has Abstract

pub_date

2019-04-01 00:00:00

pages

943-948

issue

4

eissn

1359-6446

issn

1878-5832

pii

S1359-6446(18)30507-5

journal_volume

24

pub_type

杂志文章
  • Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors.

    abstract::Epidermal growth factor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, show excellent clinical efficacy for patients with non-small cell lung cancer (NSCLC) with EGFR mutations, including Exon 19 deletion and single-point substitution, and L858R of exon 21. The reason for the reduction in e...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.10.004

    authors: Singh M,Jadhav HR

    更新日期:2018-03-01 00:00:00

  • Drug discovery for enzymes.

    abstract::Enzymes are essential, physiological catalysts involved in all processes of life, including metabolism, cellular signaling and motility, as well as cell growth and division. They are attractive drug targets because of the presence of defined substrate-binding pockets, which can be exploited as binding sites for pharma...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2021.01.006

    authors: Rufer AC

    更新日期:2021-01-14 00:00:00

  • Catabolic mediators as targets for cancer cachexia.

    abstract::The cachexia syndrome, characterized by a marked weight loss, anorexia, asthenia and anaemia, is invariably associated with the growth of a tumour and leads to a malnutrition status caused by the induction of anorexia or decreased food intake. In addition, the competition for nutrients between the tumour and the host ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/s1359-6446(03)02826-5

    authors: Argilés JM,Moore-Carrasco R,Busquets S,López-Soriano FJ

    更新日期:2003-09-15 00:00:00

  • Biomanufacturing: a high-growth industry for North Carolina.

    abstract::The sustained growth of biotechnology in North Carolina has made the state a worldwide leader in biotechnology. ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/S1359-6446(05)03650-0

    authors: Hartl B

    更新日期:2005-11-15 00:00:00

  • Updating molecular properties during early drug discovery.

    abstract::Current multiparameter optimization (MPO) strategies make use of few experimental physicochemical descriptors (i.e., solubility at physiological pH and lipophilicity in the octanol/water system). Here, we show how new trends in drug discovery (i.e., large and flexible molecules for 'difficult' targets) call for the in...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2016.11.017

    authors: Caron G,Ermondi G

    更新日期:2017-06-01 00:00:00

  • Gestational hypoxia and epigenetic programming of brain development disorders.

    abstract::Adverse environmental conditions faced by an individual early during its life, such as gestational hypoxia, can have a profound influence on the risk of diseases, such as neurological disorders, in later life. Clinical and preclinical studies suggest that epigenetic programming of gene expression patterns in response ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2014.09.010

    authors: Ma Q,Xiong F,Zhang L

    更新日期:2014-12-01 00:00:00

  • Magnetic nanoformulations for prostate cancer.

    abstract::Magnetic nanoparticles (MNPs) play a vital role for improved imaging applications. Recently, a number of studies demonstrate MNPs can be applied for targeted delivery, sustained release of therapeutics, and hyperthermia. Based on stable particle size and shape, biocompatibility, and inherent contrast enhancement chara...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.04.018

    authors: Chowdhury P,Roberts AM,Khan S,Hafeez BB,Chauhan SC,Jaggi M,Yallapu MM

    更新日期:2017-08-01 00:00:00

  • The development of molecular clamps as drugs.

    abstract::Some enzymes catalyze the modification of an ensemble of substrates in vivo and, as a consequence, are not ideal targets for active-site-directed drugs. One solution to inhibiting such multisubstrate enzymes would be a drug that binds tightly to only one substrate, which prevents the binding of that substrate to the e...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2006.07.011

    authors: Weiss ST,McIntyre NR,McLaughlin ML,Merkler DJ

    更新日期:2006-09-01 00:00:00

  • Biological networks and analysis of experimental data in drug discovery.

    abstract::Cellular life can be represented and studied as the 'interactome'--a dynamic network of biochemical reactions and signaling interactions between active proteins. Systemic networks analysis can be used for the integration and functional interpretation of high-throughput experimental data, which are abundant in drug dis...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(05)03420-3

    authors: Nikolsky Y,Nikolskaya T,Bugrim A

    更新日期:2005-05-01 00:00:00

  • WITHDRAWN: Enabling infrastructure for global health product development.

    abstract::This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy. ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2012.05.014

    authors: Satcher R,Evans-Storms RB

    更新日期:2012-06-01 00:00:00

  • The role of the 14-3-3 protein family in health, disease, and drug development.

    abstract::14-3-3 proteins regulate intracellular signaling pathways, such as signal transduction, protein trafficking, cell cycle, and apoptosis. In addition to the ubiquitous roles of 14-3-3 isoforms, unique tissue-specific functions are also described for each isoform. Owing to their role in regulating cell cycle, protein tra...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2015.09.012

    authors: Aghazadeh Y,Papadopoulos V

    更新日期:2016-02-01 00:00:00

  • Developing polyphenolic acetates as radiation countermeasure agents: current status and future perspectives.

    abstract::Total-body exposure to ionizing radiation (TBI) results in life-threatening acute radiation syndrome (ARS), which encompasses hematopoietic and gastrointestinal (GI) injuries and results in dose-dependent morbidity and mortality. Management of ARS warrants the deployment of effective medical countermeasure agents (MCM...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2020.02.004

    authors: Venkateswaran K,Shrivastava A,Prasad AK,Parmar VS,Dwarakanath BS

    更新日期:2020-04-01 00:00:00

  • 3D in vitro models of tumors expressing EGFR family receptors: a potent tool for studying receptor biology and targeted drug development.

    abstract::Carcinomas overexpressing EGFR family receptors are of high clinical importance, because the receptors have prognostic value and are used as molecular targets for anticancer therapy. Insufficient drug efficacy necessitates further in-depth research of the receptor biology and improvement in preclinical stages of drug ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2018.09.003

    authors: Sokolova EA,Vodeneev VA,Deyev SM,Balalaeva IV

    更新日期:2019-01-01 00:00:00

  • Protein-interaction networks: from experiments to analysis.

    abstract::Functional proteomics approaches aim to characterize comprehensively the function of gene products, and provide a first-level understanding of cellular mechanisms. Here, we review recent techniques for the construction and prediction of large-scale protein-interaction networks, with a particular emphasis on computatio...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/s1359-6446(02)02281-x

    authors: Schächter V

    更新日期:2002-06-01 00:00:00

  • Carbohydrate sulfotransferases: novel therapeutic targets for inflammation, viral infection and cancer.

    abstract::Effective direct inhibition of adhesion receptors by small molecules has been hampered by extended receptor-ligand interfaces as well as the entropic penalties often associated with inhibition of cell adhesion. Therefore, alternative strategies have targeted enzymes that are centrally involved in the biosynthesis of r...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(00)01581-6

    authors: Hemmerich S

    更新日期:2001-01-01 00:00:00

  • PLK1 as an oncology target: current status and future potential.

    abstract::The Polo-like kinases (PLKs) have been investigated as oncology targets for several years; however, only recently have potent inhibitors been described. Here, we report on progress in the clinical validation of the PLKs as antitumor drug targets as well as recent understanding gained regarding their synergistic roles ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2011.05.002

    authors: McInnes C,Wyatt MD

    更新日期:2011-07-01 00:00:00

  • An update on the role of nanovehicles in nose-to-brain drug delivery.

    abstract::A quantitative analysis has cast doubt over the limited advantages provided by particles for nose-to-brain (NTB) drug delivery. Thus, it is imperative to identify the role of nanovehicles in NTB drug delivery. If nanocarriers are used merely as an option to improve various properties of the drugs or the formulations, ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2018.01.005

    authors: Feng Y,He H,Li F,Lu Y,Qi J,Wu W

    更新日期:2018-05-01 00:00:00

  • Supramolecular devices to improve the treatment of brain diseases.

    abstract::The blood-brain barrier (BBB) hinders the accumulation of active compounds in the central nervous system, thus decreasing their therapeutic effectiveness. To overcome this obstacle, interesting supramolecular nanodevices are herein considered. These systems have many advantages over the conventional formulations, such...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2011.02.006

    authors: Paolino D,Cosco D,Molinaro R,Celia C,Fresta M

    更新日期:2011-04-01 00:00:00

  • Enhancing the potential preclinical and clinical benefits of quercetin through novel drug delivery systems.

    abstract::Quercetin is reported to have numerous pharmacological actions, including antidiabetic, anti-inflammatory and anticancer activities. The main mechanism responsible for its pharmacological activities is its ability to quench reactive oxygen species (ROS) and, hence, decrease the oxidative stress responsible for the dev...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.11.001

    authors: Khursheed R,Singh SK,Wadhwa S,Gulati M,Awasthi A

    更新日期:2020-01-01 00:00:00

  • What is precise pathophysiology in development of hypertension in pregnancy? Precision medicine requires precise physiology and pathophysiology.

    abstract::It is widely accepted that placental ischemia is central in the evolution of hypertension in pregnancy. Many studies and reviews have targeted placental ischemia to explain mechanisms for initiating pregnancy hypertension. The placenta is rich in blood vessels, which are the basis for developing placental ischemia. Ho...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.10.021

    authors: Gao Q,Tang J,Li N,Liu B,Zhang M,Sun M,Xu Z

    更新日期:2018-02-01 00:00:00

  • Target discovery from data mining approaches.

    abstract::Data mining of available biomedical data and information has greatly boosted target discovery in the 'omics' era. Target discovery is the key step in the biomarker and drug discovery pipeline to diagnose and fight human diseases. In biomedical science, the 'target' is a broad concept ranging from molecular entities (s...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2011.12.006

    authors: Yang Y,Adelstein SJ,Kassis AI

    更新日期:2012-02-01 00:00:00

  • The power of combining phenotypic and target-focused drug discovery.

    abstract::A fierce dispute has arisen between the supporters of phenotypic and target-focused screening regarding which path grants the higher probability of successful drug development. A chance to reconcile these two approaches lies in successful target deconvolution (TD) after phenotypic screens. But, despite the panoply of ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2018.10.009

    authors: Heilker R,Lessel U,Bischoff D

    更新日期:2019-02-01 00:00:00

  • Extending kinome coverage by analysis of kinase inhibitor broad profiling data.

    abstract::The explored kinome was extended with broad profiling using the DiscoveRx and Millipore assay panels. The analysis of the profiling of 3368 selected inhibitors on 456 kinases in the DiscoveRx format delivered several insights. First, the coverage depended on the threshold of the selectivity parameter. Second, the rela...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2015.01.002

    authors: Jacoby E,Tresadern G,Bembenek S,Wroblowski B,Buyck C,Neefs JM,Rassokhin D,Poncelet A,Hunt J,van Vlijmen H

    更新日期:2015-06-01 00:00:00

  • Functionalizing bioinks for 3D bioprinting applications.

    abstract::3D bioprinting has emerged as the intersection between chemistry, biology and technology. Through its integration of cells, biocompatible materials and robotic-controlled dispensing systems, the process enables the production of structures that are biomimetic and functional, thus revolutionizing the concept of tissue ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2018.09.012

    authors: Parak A,Pradeep P,du Toit LC,Kumar P,Choonara YE,Pillay V

    更新日期:2019-01-01 00:00:00

  • Where is the hope for drug discovery? Let history tell the future.

    abstract::For drug discovery, historical experience is always of significance. Through examining the history of traditional medicines, we find that these medicines have more implications for drug discovery than just providing new chemical entities. The history of traditional medicines indicates that they depended more on the co...

    journal_title:Drug discovery today

    pub_type: 历史文章,杂志文章

    doi:10.1016/j.drudis.2008.07.002

    authors: Kong DX,Li XJ,Zhang HY

    更新日期:2009-02-01 00:00:00

  • Physicochemical properties affecting the fate of nanoparticles in pulmonary drug delivery.

    abstract::The inhaled delivery of nanomedicines has attracted much attention in the treatment of lung diseases or systemic diseases. However, there is a lack of understanding about their fate upon lung delivery. Thus, the objective of this review is to summarize physicochemical properties affecting the fate of nanoparticles aft...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.09.023

    authors: Liu Q,Guan J,Qin L,Zhang X,Mao S

    更新日期:2020-01-01 00:00:00

  • Delivery of small molecules for bone regenerative engineering: preclinical studies and potential clinical applications.

    abstract::Stimulation of bone regeneration using growth factors is a promising approach for musculoskeletal regenerative engineering. However, common limitations with protein growth factors, such as high manufacturing costs, protein instability, contamination issues, and unwanted immunogenic responses of the host reduce potenti...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2014.01.012

    authors: Laurencin CT,Ashe KM,Henry N,Kan HM,Lo KW

    更新日期:2014-06-01 00:00:00

  • FDA-approved drug labeling for the study of drug-induced liver injury.

    abstract::Drug-induced liver injury (DILI) is a leading cause of drugs failing during clinical trials and being withdrawn from the market. Comparative analysis of drugs based on their DILI potential is an effective approach to discover key DILI mechanisms and risk factors. However, assessing the DILI potential of a drug is a ch...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2011.05.007

    authors: Chen M,Vijay V,Shi Q,Liu Z,Fang H,Tong W

    更新日期:2011-08-01 00:00:00

  • Pharmacological treatment of idiopathic pulmonary fibrosis: an update.

    abstract::Idiopathic pulmonary fibrosis (IPF) is a progressive and almost invariably lethal disease that affects primarily older adults. After a decade of negative (or inconsistent) results, two recent clinical trials have demonstrated that slowing disease progression with medication is possible. An improved understanding of di...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2015.01.001

    authors: Spagnolo P,Wells AU,Collard HR

    更新日期:2015-05-01 00:00:00

  • Drug delivery systems and novel formulations to improve treatment of rare corneal disease.

    abstract::As the field of ocular drug delivery grows so does the potential for novel drug discovery or reformulation in lesser-known diseases of the eye. In particular, rare corneal diseases are an interesting area of research because drug delivery is limited to the outermost tissue of the eye. This review will highlight the op...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.03.005

    authors: Jimenez J,Sakthivel M,Nischal KK,Fedorchak MV

    更新日期:2019-08-01 00:00:00